Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T W Jones

Showing results (321-330 of 589) with videos related to

Pageof 59
Sort By:
The Lancet. Oncology|July 6, 2017
From class waivers to precision medicine in paediatric oncologyAndrew D J Pearson, Stefan M Pfister, Andre Baruchel, et al.
Neuro-Oncology|November 23, 2017
Feasibility of real-time molecular profiling for patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation-the NCT Neuro Master Match (N2M2) pilot studyElke Pfaff, Tobias Kessler, Gnana Prakash Balasubramanian, et al.
Acta Neuropathologica|March 11, 2015
Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markersAndrey Korshunov, Marina Ryzhova, Volker Hovestadt, et al.
Neuro-Oncology|April 17, 2025
A Phase 2 PBTC Study of Selumetinib for Recurrent/Progressive Pediatric Low-Grade Glioma: Strata 2, 5, and 6 with Long-term Outcomes on Strata 1, 3, and 4Jason Fangusaro, Arzu Onar-Thomas, Tina Young Poussaint, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|July 27, 2021
Intimal sarcomas and undifferentiated cardiac sarcomas carry mutually exclusive MDM2, MDM4, and CDK6 amplifications and share a common DNA methylation signatureChristian Koelsche, Jamal K Benhamida, Felix K F Kommoss, et al.
BMC Cancer|June 7, 2020
INFORM2 NivEnt: The first trial of the INFORM2 biomarker driven phase I/II trial series: the combination of nivolumab and entinostat in children and adolescents with refractory high-risk malignanciesCornelis M van Tilburg, Ruth Witt, Melanie Heiss, et al.
Brain Pathology (Zurich, Switzerland)|April 22, 2018
EWSR1-PATZ1 gene fusion may define a new glioneuronal tumor entityAurore Siegfried, Audrey Rousseau, Claude-Alain Maurage, et al.
Journal of Translational Medicine|June 5, 2023
Group-specific cellular metabolism in MedulloblastomaViktoria L E Funke, Carolin Walter, Viktoria Melcher, et al.
Acta Neuropathologica|August 14, 2012
Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutationsXiao-Yang Liu, Noha Gerges, Andrey Korshunov, et al.
European Journal of Cancer (Oxford, England : 1990)|December 21, 2022
Molecular diagnostics enables detection of actionable targets: the Pediatric Targeted Therapy 2.0 registryJonas Ecker, Florian Selt, Dominik Sturm, et al.
Pageof 59

Showing results (321-330 of 589) with videos related to

Sort By:
Pageof 59
The Lancet. Oncology|July 6, 2017
From class waivers to precision medicine in paediatric oncologyAndrew D J Pearson, Stefan M Pfister, Andre Baruchel, et al.
Neuro-Oncology|November 23, 2017
Feasibility of real-time molecular profiling for patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation-the NCT Neuro Master Match (N2M2) pilot studyElke Pfaff, Tobias Kessler, Gnana Prakash Balasubramanian, et al.
Acta Neuropathologica|March 11, 2015
Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markersAndrey Korshunov, Marina Ryzhova, Volker Hovestadt, et al.
Neuro-Oncology|April 17, 2025
A Phase 2 PBTC Study of Selumetinib for Recurrent/Progressive Pediatric Low-Grade Glioma: Strata 2, 5, and 6 with Long-term Outcomes on Strata 1, 3, and 4Jason Fangusaro, Arzu Onar-Thomas, Tina Young Poussaint, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|July 27, 2021
Intimal sarcomas and undifferentiated cardiac sarcomas carry mutually exclusive MDM2, MDM4, and CDK6 amplifications and share a common DNA methylation signatureChristian Koelsche, Jamal K Benhamida, Felix K F Kommoss, et al.
BMC Cancer|June 7, 2020
INFORM2 NivEnt: The first trial of the INFORM2 biomarker driven phase I/II trial series: the combination of nivolumab and entinostat in children and adolescents with refractory high-risk malignanciesCornelis M van Tilburg, Ruth Witt, Melanie Heiss, et al.
Brain Pathology (Zurich, Switzerland)|April 22, 2018
EWSR1-PATZ1 gene fusion may define a new glioneuronal tumor entityAurore Siegfried, Audrey Rousseau, Claude-Alain Maurage, et al.
Journal of Translational Medicine|June 5, 2023
Group-specific cellular metabolism in MedulloblastomaViktoria L E Funke, Carolin Walter, Viktoria Melcher, et al.
Acta Neuropathologica|August 14, 2012
Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutationsXiao-Yang Liu, Noha Gerges, Andrey Korshunov, et al.
European Journal of Cancer (Oxford, England : 1990)|December 21, 2022
Molecular diagnostics enables detection of actionable targets: the Pediatric Targeted Therapy 2.0 registryJonas Ecker, Florian Selt, Dominik Sturm, et al.
Pageof 59